We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
Read MoreHide Full Article
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Bayer Aktiengesellschaft (BAYRY - Free Report) and Roche Holding AG (RHHBY - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
Right now, Bayer Aktiengesellschaft is sporting a Zacks Rank of #1 (Strong Buy), while Roche Holding AG has a Zacks Rank of #3 (Hold). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that BAYRY is likely seeing its earnings outlook improve to a greater extent. But this is just one piece of the puzzle for value investors.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
BAYRY currently has a forward P/E ratio of 8.80, while RHHBY has a forward P/E of 15.74. We also note that BAYRY has a PEG ratio of 3.52. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. RHHBY currently has a PEG ratio of 4.26.
Another notable valuation metric for BAYRY is its P/B ratio of 1.47. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, RHHBY has a P/B of 7.23.
Based on these metrics and many more, BAYRY holds a Value grade of B, while RHHBY has a Value grade of C.
BAYRY sticks out from RHHBY in both our Zacks Rank and Style Scores models, so value investors will likely feel that BAYRY is the better option right now.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Bayer Aktiengesellschaft (BAYRY - Free Report) and Roche Holding AG (RHHBY - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.
Right now, Bayer Aktiengesellschaft is sporting a Zacks Rank of #1 (Strong Buy), while Roche Holding AG has a Zacks Rank of #3 (Hold). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that BAYRY is likely seeing its earnings outlook improve to a greater extent. But this is just one piece of the puzzle for value investors.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
BAYRY currently has a forward P/E ratio of 8.80, while RHHBY has a forward P/E of 15.74. We also note that BAYRY has a PEG ratio of 3.52. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. RHHBY currently has a PEG ratio of 4.26.
Another notable valuation metric for BAYRY is its P/B ratio of 1.47. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, RHHBY has a P/B of 7.23.
Based on these metrics and many more, BAYRY holds a Value grade of B, while RHHBY has a Value grade of C.
BAYRY sticks out from RHHBY in both our Zacks Rank and Style Scores models, so value investors will likely feel that BAYRY is the better option right now.